Koers Aurinia Pharmaceuticals Inc. Toronto S.E.
Aandelen
AUP
CA05156V1022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 223 mln. 302 mln. 207 mln. | Omzet 2025 * | 288 mln. 390 mln. 266 mln. | Marktkapitalisatie | 725 mln. 981 mln. 671 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -6 mln. -8,13 mln. -5,56 mln. | Nettowinst (verlies) 2025 * | 58 mln. 78,56 mln. 53,73 mln. | EV/omzet 2024 * | 1,7 x |
Nettoliquiditeiten 2024 * | 344 mln. 466 mln. 319 mln. | Nettoliquiditeiten 2025 * | 390 mln. 529 mln. 362 mln. | EV/omzet 2025 * | 1,16 x |
K/w-verhouding 2024 * |
-91,1
x | K/w-verhouding 2025 * |
12,7
x | Werknemers | 300 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,55% |
Recentste transcriptie over Aurinia Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16-06-93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Robert Foster
FOU | Founder | 65 | 16-06-93 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16-06-93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26-06-19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-35,36% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. |